Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a novel class of biologic therapy to ...

CLINICAL BENEFIT, INCLUDING CAFS AND SURVIVAL, IS GREATEST IN A SUBGROUP OF ALS PATIENTS THAT SERVES AS THE BASIS FOR THE RECENTLY AUTHORIZED PHASE 3 CONFIRMATORY STUDY ...

Dean’s Honored Graduates for the class of 2025 in the College of Natural Sciences at The University of Texas at Austin ...

Co., LTD. received IND clearance from the FDA to initiate Phase 1 clinical trial in the United States for its NTS071, a novel small molecule allosteric reactivator targeting p53 Y220C mutation. NTS071 ...

A Reddit thread challenged the notion that “ghar ka khana” (homemade food) automatically supports fitness goals. Users warned ...

Preclinical data on AbCellera’s PSMA x CD3 T-cell engagers demonstrate potent anti-tumor activity and potential to further ...

A breakthrough in preclinical data puts CK Life Sciences at the forefront of next-gen immuno-oncology. Abstract 853: PDL1-PRAME dual antigen cancer vaccine inhibits melanoma growth in syngeneic mouse ...

It’s like paleo had a chaotic love child with a protein shake. And while social media might have ... Brian Johnson – better ...

Matthew DeYoung Investor Relations and Media Argot Partners [email protected] Repare Therapeutics Inc. ("Repare" or the "Company") (Nasdaq: RPTX), a leading clinical-stage precision oncology ...